Close Menu

Medical Imaging

News on medical imaging technologies and applications.

In one of its partnerships, Gestalt will work to integrate Flagship Bioscience's machine learning tools to enable cancer biomarker detection.

The deal with AstraZeneca follows a licensing agreement signed earlier this year with Memorial Sloan Kettering Cancer Center also covering radionuclide PARP inhibitor IP.

The companies are developing PET tracers based on Indi's affinity agent technology that will allow for imaging-based detection of cytotoxic T lymphocyctes.